Policy & Regulation
4basebio announces award of GMP certification for UK DNA manufacturing facility
2 April 2025 - Biotechnology company 4basebio PLC (AIM: 4BB) announced on Wednesday that it has obtained Good Manufacturing Practice (GMP) certification from the UK's Medicines and Healthcare Pro...
Ananda Pharma's MRX1 receives ethics approval for Phase 1 study in Australia
2 April 2025 - UK-based biopharmaceutical company Ananda Pharma plc (AQSE: ANA) announced on Wednesday that it has received approval from the Alfred Hospital Human Research Ethics Committee (HREC) in ...
GRIN Therapeutics' radiprodil granted Priority Medicine designation in Europe
2 April 2025 - GRIN Therapeutics Inc, a developer of therapies to treat serious neurodevelopmental disorders, announced on Tuesday that it has received Priority Medicine (PRIME) designation for radipr...
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
2 April 2025 - AKAGERA Medicines Inc, a biotech company developing novel lipid nanoparticle formulations of antibacterial drugs and mRNA vaccines to treat tuberculosis, avian flu, RSV and other infect...
Yingli Pharma's linperlisib Phase 3 registration study approved by US FDA
2 April 2025 - Chinese clinical stage biotechnology company Shanghai Yingli Pharmaceutical Co Ltd (Yingli Pharma) announced on Tuesday that it has received approval from the US Food and Drug Administr...
Oncopeptides secures FDA approval to resume OPD5 clinical development
1 April 2025 - Oncopeptides AB (STO:ONCO), a Swedish biotech company focused on difficult-to-treat cancers, announced on Tuesday that the US Food and Drug Administration (FDA) has lifted the clinical ...